

IGFBP 5 Human

Description: IGFBP5 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 253 amino acids and having a molecular mass of 28613 Dalton. IGFBP5 is purified by proprietary chromatographic techniques.

Synonyms: IGFBP-5, IBP-5, IGF-binding protein 5.

Source: Escherichia Coli.

Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.

Amino Acid Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Met-Leu-Gly-Ser-Phe.

Purity: Greater than 98.0% as determined by:(a) Analysis by RP-HPLC.(b) Analysis by SDS-PAGE.

Formulation:

IBP-5 was lyophilized from a concentrated (1mg/ml) solution containing 10mM sodium Citrate PH 3.0.

Stability:

Lyophilized IBP5 although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution IGFBP 5 should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Please prevent freeze-thaw cycles.

Usage:

ProSec's products are furnished for LABORATORY RESEARCH USE ONLY. They may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

Solubility:

It is recommended to reconstitute the lyophilized Insulin-Like Growth Factor Binding Protein-5 in sterile 18M-cm H₂O not less than 100μg/ml, which can then be further diluted to other aqueous solutions.

Introduction:

IGFBP5 is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

Biological Activity:

The ED50, calculated by its ability to inhibit IGF-II induced proliferation of MCF-7 is < 0.3

References:

Title: Effects of Dietary Carbohydrate Modification in Persons with the Metabolic Syndrome- A

www.neobiolab.com

info@neobiolab.com

888.754.5670, +1 617.500.7103 United States

0800.088.5164, +44 020.8123.1558 United Kingdom

Transcriptomics Approach in Adipose Tissue Publication: Department of Clinical Nutrition, Food and

Health Research Centre Institute of Public Health and Clinical Nutrition Faculty of Health

Sciences University of Eastern Finland Kuopio

2010 Link: http://epublications.uef.fi/pub/urn_isbn_978-952-61-0024-1/urn_isbn_978-952-61-0024-1

.pdf

To place an order, please Click HERE.



Catalog #: CYPS-471

For research use only.



neobiolab | Term | Quote/Order | Services | Products | Support | Corporate | Contact Us
Copyrights @ 2013 NEO Group 245 First Street, 18th Floor, Cambridge MA 02142 888.754.5670 (toll-free)



Request a
CATALOG
CLICK HERE